Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas

Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas

The BRAFV600E mutation, which in melanoma is targetable with vemurafenib, is also found in sarcomas and we here evaluate the therapeutic potential in sarcoma cell lines. Methods: Four sarcoma cell lines harboring the BRAFV600E mutation, representing liposarcomas (SA-4 and SW872), Ewing sarcoma (A673...

Full description

Bibliographic Details
Main Authors:	Sarina Gouravan, Leonardo A. Meza-Zepeda, Ola Myklebost, Eva W. Stratford, Else Munthe
Format:	Article
Language:	English
Published:	MDPI AG 2018-03-01
Series:	International Journal of Molecular Sciences
Subjects:	BRAF precision medicine drug repurposing
Online Access:	http://www.mdpi.com/1422-0067/19/4/969

Similar Items

Sarcoidosis is not associated with BRAFV600E mutation
by: Christian D. Becker, et al.
Published: (2017-01-01)

S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib
by: Xuelong Jiao, et al.
Published: (2018-09-01)

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review
by: Andrews, L.J, et al.
Published: (2022)

Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
by: Elzbieta Nowara, et al.
Published: (2016-02-01)

Plasma proteome alterations by MAPK inhibitors in BRAFV600-mutated metastatic cutaneous melanoma
by: Haris Babačić, et al.
Published: (2021-08-01)

Impact of MAPK Pathway Activation in BRAFV600 Melanoma on T Cell and Dendritic Cell Function
by: Patrick A. Ott, et al.
Published: (2013-10-01)

Onset of vitiligo following targeted therapy for BRAFV600E-mutated melanoma: case report
by: Sonia Brugnara, et al.
Published: (2019-12-01)

BRAFV600E mutation impinges on gut microbial markers defining novel biomarkers for serrated colorectal cancer effective therapies
by: Nadia Trivieri, et al.
Published: (2020-12-01)

Extended Antitumor Responseof a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
by: Siraj M. Ali, et al.
Published: (2014-05-01)

Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
by: Lu Si, et al.
Published: (2018-05-01)

BRAFV600E mutation, BRAF-activated long non-coding RNA and miR-9 expression in papillary thyroid carcinoma, and their association with clinicopathological features
by: Chenlei Shi, et al.
Published: (2020-06-01)

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
by: Ester Simeone, et al.
Published: (2021-01-01)

Co-existence of BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis
by: Ren HY, et al.
Published: (2018-05-01)

Baseline Genomic Features in <i>BRAFV600</i>-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
by: Baptiste Louveau, et al.
Published: (2019-08-01)

Association between clinicopathologic characteristics and BRAFV600E expression in Chinese patients with Langerhans cell histiocytosis
by: Hui Huang, et al.
Published: (2019-10-01)

The role of BRAF V600 mutation in melanoma
by: Ascierto Paolo A, et al.
Published: (2012-07-01)

Mutationally-activated PI3’-kinase-α promotes de-differentiation of lung tumors initiated by the BRAFV600E oncoprotein kinase
by: J Edward van Veen, et al.
Published: (2019-08-01)

Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report
by: Morgane Broudic-Guibert, et al.
Published: (2019-07-01)

Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation
by: Fedor V. Moiseyenko, et al.
Published: (2019-05-01)

Coexistence of BRAFV600E mutation and EGFR overexpression is highly associated with adverse clinicopathological features of papillary thyroid carcinoma
by: Paunović Ivan, et al.
Published: (2020-01-01)

BRAF mutation and its inhibitors in sarcoma treatment
by: Haotian Liu, et al.
Published: (2020-07-01)

Delayed-onset vemurafenib-induced panniculitis
by: Stephen L. Vance, MD, MBA, et al.
Published: (2017-09-01)

Predictive Factors of Recurrence for Multifocal Papillary Thyroid Microcarcinoma With Brafv600e Mutation: A Single Center Study of 1,207 Chinese Patients
by: Shuai Xue, et al.
Published: (2019-06-01)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
by: Tiziana Notarangelo, et al.
Published: (2017-10-01)

Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E‐mutated lung adenocarcinoma
by: Takayo Ota, et al.
Published: (2021-10-01)

The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study
by: Ebner, R., et al.
Published: (2022)

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma
by: Joseph I. Clark, et al.
Published: (2018-07-01)

Molecular testing for BRAFV600E and RAS mutations from cytoscrapes of thyroid fine needle aspirates: A single-center pilot study
by: Ojas Gupta, et al.
Published: (2020-01-01)

Metastatic melanoma and vemurafenib: novel approaches
by: Ramon Andrade De Mello
Published: (2012-04-01)

Metastatic Colorectal Cancer Patient With Microsatellite Stability and BRAFV600E Mutation Showed a Complete Metabolic Response to PD-1 Blockade and Bevacizumab: A Case Report
by: Chongkai Fang, et al.
Published: (2021-04-01)

Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib
by: Castellani Elisa, et al.
Published: (2012-07-01)

BRAFAMP Frequently Co-occurs With IDH1/2, TP53, and ATRX Mutations in Adult Patients With Gliomas and Is Associated With Poorer Survival Than That of Patients Harboring BRAFV600E
by: Rong Da, et al.
Published: (2021-01-01)

MLH1–93 G/a polymorphism is associated with MLH1 promoter methylation and protein loss in dysplastic sessile serrated adenomas with BRAFV600E mutation
by: Lochlan J. Fennell, et al.
Published: (2018-01-01)

Prolonged Response Induced by Single Agent Vemurafenib in a BRAF V600E Spinal Ganglioglioma: A Case Report and Review of the Literature
by: Louis Garnier, et al.
Published: (2019-03-01)

Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma
by: Hilal Eser Öztürk, et al.
Published: (2020-01-01)

RNA sequencing data of Vemurafenib-resistant melanoma cells and parental cells
by: Kun Zhao, et al.
Published: (2020-06-01)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
by: Francesca Consoli, et al.
Published: (2020-07-01)

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma
by: Priscilla Denise Zepeda-Lopez, et al.
Published: (2016-04-01)

V-raf murine sarcoma viral oncogene homolog B (BRAF) mutations in hairy cell leukaemia
by: Neeraj Arora, et al.
Published: (2015-01-01)

Apparent Lack of BRAFV600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis
by: Paul G. Kemps, et al.
Published: (2020-01-01)